Skip Navigation
Department of Health and Human Services www.hhs.gov
 
Slide Tray
0 slides

Return to Slide Library

Slides

Add Presentation to Slide Tray Presentation:

First- and Second-Generation Antipsychotics for Children and Young Adults

Slide: 28 of 43

Summary of Comparative Effectiveness Results (1 of 2)

The evidence from within-class comparisons of first-generation antipsychotics (FGAs) with each other for pediatric use is insufficient to permit conclusions about effect sizes and statistical significance.

In between-class comparisons of FGAs with second-generation antipsychotics (SGAs) for pediatric use:

  • Olanzapine and risperidone are more effective than haloperidol for reducing autistic symptoms in pervasive developmental disorders. The strength of evidence for this finding is low.
  • SGAs (clozapine, olanzapine, and risperidone) are more effective than haloperidol in treating schizophrenia, as assessed by clinical global impressions, but not by effects on positive and negative symptoms. The strength of evidence for this finding is low.